The International Conference on Molecular Targets and Therapeutics, jointly sponsored by
the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and …

The advent of targeted therapy for treatment of human cancers has added significantly to our
armamentarium as we strive to prolong patient survival while minimizing toxicity. In cancers …

As our understanding of the mechanisms of cytotoxic drug resistance improves, it becomes
feasible to circumvent this resistance through the rational design of non cross-resistant …

Targeted therapies in cancer aim to specifically block the activity of crucial proteins or
signaling pathways necessary for the growth and/or survival of tumor cells. A major …

Toxic chemotherapeutic agents are slowly being supplemented by a new generation of
drugs that recognize specific targets in or on cancer cells. Although these molecular and …

The development of new anticancer drugs and the identification of novel targets represent
major focus areas for pharmaceutical and biotech companies, universities and research …

Drug resistance has always been a concern in cancer treatment, often blamed on the
genetic complexity and instability of tumor cells. While studies of cancer cell lines have …

Treatment resistance, whether inherent or acquired, is a major problem reducing the activity
of conventional and newer, molecularly targeted, cancer drugs. A more complex picture of …

Targeted therapies can be defined as drugs developed against a specific target based on its
important biological function in cancer. In contrast, nontargeted therapies are drugs …

Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …